Clinical Trial Update: JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating JS207 in combination with JS007 as first-line therapy for advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• JS007
• JS207

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING